Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 8/20 | 0.78 |
| ▸ | ESR1 | P03372 | 4/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.78 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.78 |
| ▸ | MAPT | P10636 | 1/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
| ▸ | ATM | Q13315 | 1/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.78 |
| ▸ | ACHE | P22303 | 2/20 | 0.68 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | APEX1 | P27695 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.65 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.65 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.65 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17387051 | 0.90 | CACNA1H (0.77) | CACNA1HESR1KMT2ACACNA1GMAPT | |
| SCHEMBL145713 | 0.88 | CACNA1H (1.00) | CACNA1HESR1KMT2ACACNA1GMAPT | |
| SCHEMBL29394512 | 0.88 | CACNA1H (1.00) | CACNA1HESR1KMT2ACACNA1GMAPT | |
| SCHEMBL145714 | 0.88 | CACNA1H (1.00) | CACNA1HESR1KMT2ACACNA1GMAPT | |
| SCHEMBL22465222 | 0.86 | CACNA1H (1.00) | CACNA1HESR1KMT2ACACNA1GMAPT | |
| SCHEMBL22465338 | 0.86 | CACNA1H (1.00) | CACNA1HESR1KMT2ACACNA1GMAPT | |
| SCHEMBL22465737 | 0.84 | CACNA1H (0.85) | CACNA1HESR1KMT2ACACNA1GMAPT | |
| SCHEMBL17387170 | 0.84 | CACNA1H (0.78) | CACNA1HESR1KMT2ACACNA1GMAPT | |
| SCHEMBL15824268 | 0.83 | ESR1 (0.77) | CACNA1HESR1KMT2ACACNA1GMAPT | |
| SCHEMBL476289 | 0.82 | PLK1 (0.80) | CACNA1HESR1KMT2ACACNA1GMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160130245-A1 | 6,8-SUBSTITUTED NARINGENIN DERIVATIVE AND USE THEREOF | SUN YAT-SEN UNIVERSITY (CN) | 2016-05-12 | — | — | US | claimed |
| EP-2963030-A1 | 6,8-SUBSTITUTED NARINGENIN DERIVATIVE AND USE THEREOF | Sun Yat-Sen University (CN) | 2016-01-06 | — | — | EP | claimed |
| US-20160130245-A1 | 6,8-SUBSTITUTED NARINGENIN DERIVATIVE AND USE THEREOF | SUN YAT-SEN UNIVERSITY (CN) | 2016-05-12 | — | — | US | disclosed |
| US-20160130245-A1 | 6,8-SUBSTITUTED NARINGENIN DERIVATIVE AND USE THEREOF | SUN YAT-SEN UNIVERSITY (CN) | 2016-05-12 | — | — | US | disclosed |
| US-20160130245-A1 | 6,8-SUBSTITUTED NARINGENIN DERIVATIVE AND USE THEREOF | SUN YAT-SEN UNIVERSITY (CN) | 2016-05-12 | — | — | US | disclosed |
| EP-2963030-A1 | 6,8-SUBSTITUTED NARINGENIN DERIVATIVE AND USE THEREOF | Sun Yat-Sen University (CN) | 2016-01-06 | — | — | EP | disclosed |
| EP-2963030-A1 | 6,8-SUBSTITUTED NARINGENIN DERIVATIVE AND USE THEREOF | Sun Yat-Sen University (CN) | 2016-01-06 | — | — | EP | disclosed |
| CN-103012348-B | 6,8-substituted naringenin derivative and application thereof | SU WEIWEI | 2015-04-08 | — | — | CN | disclosed |
| CN-103012348-A | 6,8-substituted naringenin derivative and application thereof | GUANGZHOU ZHONGTIAN KANGSHUN BIOLOG MEDICINE CO LTD | 2013-04-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130245-A1 | 6,8-SUBSTITUTED NARINGENIN DERIVATIVE AND USE THEREOF | CYP2C8, CYP2B6, CYP2A6 | CACNA1H 2396/4885ESR1 4446/4885KMT2A 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.